These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1581215)

  • 1. A patient with von Willebrand's disease characterized by a compound heterozygosity for a substitution of Arg854 by Gln in the putative factor-VIII-binding domain of von Willebrand factor (vWF) on one allele and very low levels of mRNA from the second vWF allele.
    Peerlinck K; Eikenboom JC; Ploos Van Amstel HK; Sangtawesin W; Arnout J; Reitsma PH; Vermylen J; Briët E
    Br J Haematol; 1992 Mar; 80(3):358-63. PubMed ID: 1581215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel case of compound heterozygosity with "Normandy"/type I von Willebrand disease (vWD). Direct demonstration of the segregation of one allele with a defective expression at the mRNA level causing type I vWD.
    Siguret V; Lavergne JM; Chérel G; Boyer-Neumann C; Ribba AS; Bahnak BR; Meyer D; Piétu G
    Hum Genet; 1994 Feb; 93(2):95-102. PubMed ID: 7906671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease.
    Kroner PA; Friedman KD; Fahs SA; Scott JP; Montgomery RR
    J Biol Chem; 1991 Oct; 266(29):19146-9. PubMed ID: 1918030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels.
    Hickson N; Hampshire D; Winship P; Goudemand J; Schneppenheim R; Budde U; Castaman G; Rodeghiero F; Federici AB; James P; Peake I; Eikenboom J; Goodeve A;
    J Thromb Haemost; 2010 Sep; 8(9):1986-93. PubMed ID: 20492463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of two point mutations in the von Willebrand factor gene of three families with the 'Normandy' variant of von Willebrand disease.
    Gaucher C; Mercier B; Jorieux S; Oufkir D; Mazurier C
    Br J Haematol; 1991 Aug; 78(4):506-14. PubMed ID: 1832934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of a unique von Willebrand disease variant. A novel mutation affecting von Willebrand factor/factor VIII interaction.
    Cacheris PM; Nichols WC; Ginsburg D
    J Biol Chem; 1991 Jul; 266(21):13499-502. PubMed ID: 1906877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel mutation in the D3 domain of von Willebrand factor markedly decreases its ability to bind factor VIII and affects its multimerization.
    Jorieux S; Gaucher C; Goudemand J; Mazurier C
    Blood; 1998 Dec; 92(12):4663-70. PubMed ID: 9845532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional analysis of the Arg91Gln substitution in the factor VIII binding domain of von Willebrand factor demonstrates variable phenotypic expression.
    Lavergne JM; Piao Y; Ribba AS; Girma JP; Siguret V; Piétu G; Boyer-Neumann C; Schandelong A; Bahnak BR; Meyer D
    Thromb Haemost; 1993 Oct; 70(4):691-6. PubMed ID: 8115998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A common splice site mutation is shared by two families with different type 2N von Willebrand disease mutations.
    Nesbitt IM; Hampton KK; Preston FE; Peake IR; Goodeve AC
    Thromb Haemost; 1999 Sep; 82(3):1061-4. PubMed ID: 10494764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2N von Willebrand disease due to Arg91Gln substitution and a cytosine deletion in exon 18 of the von Willebrand factor gene.
    Casonato A; Gaucher C; Pontara E; Zucchetto A; Zerbinati P; Mazurier C; Girolami A
    Br J Haematol; 1998 Oct; 103(1):39-41. PubMed ID: 9792286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor.
    Kroner PA; Foster PA; Fahs SA; Montgomery RR
    Blood; 1996 Feb; 87(3):1013-21. PubMed ID: 8562925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide.
    Hilbert L; Nurden P; Caron C; Nurden AT; Goudemand J; Meyer D; Fressinaud E; Mazurier C;
    Thromb Haemost; 2006 Sep; 96(3):290-4. PubMed ID: 16953269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Von Willebrand's disease caused by compound heterozygosity for a substitution mutation (T1156M) in the D3 domain of the von Willebrand factor and a stop mutation (Q2470X).
    Lethagen S; Isaksson C; Schaedel C; Holmberg L
    Thromb Haemost; 2002 Sep; 88(3):421-6. PubMed ID: 12353070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe type III von Willebrand's disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual.
    Peake IR; Liddell MB; Moodie P; Standen G; Mancuso DJ; Tuley EA; Westfield LA; Sorace JM; Sadler JE; Verweij CL
    Blood; 1990 Feb; 75(3):654-61. PubMed ID: 2297569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a His54Gln substitution in von Willebrand factor from a patient with defective binding of factor VIII.
    Rick ME; Krizek DM
    Am J Hematol; 1996 Apr; 51(4):302-6. PubMed ID: 8602631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defects in type IIA von Willebrand disease: a cysteine 509 to arginine substitution in the mature von Willebrand factor disrupts a disulphide loop involved in the interaction with platelet glycoprotein Ib-IX.
    Lavergne JM; De Paillette L; Bahnak BR; Ribba AS; Fressinaud E; Meyer D; Pietu G
    Br J Haematol; 1992 Sep; 82(1):66-72. PubMed ID: 1419804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An HphI-polymorphism in exon 28 of the von Willebrand factor gene, and its frequency among patients with various forms of von Willebrand's disease.
    Donnér M; Holmberg L; Kristoffersson AC; Nilsson IM
    Br J Haematol; 1991 Jul; 78(3):403-7. PubMed ID: 1873222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA.
    Ginsburg D; Konkle BA; Gill JC; Montgomery RR; Bockenstedt PL; Johnson TA; Yang AY
    Proc Natl Acad Sci U S A; 1989 May; 86(10):3723-7. PubMed ID: 2786201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.